Revenue segments as reported by the company.

Cannabis revenue

Distribution revenue

Beverage alcohol revenue

Wellness revenue

Adult-use

Canada - Medical

International - Medical

Bulk

Hemp

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Impairment of Assets

Litigation settlement

Transaction costs

Change in fair value of contingent consideration

Restructuring costs

Other than temporary change in fair value of convertible notes receivable

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Tilray Brands

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Tilray Brands reports record revenue and optimistic outlook for 2025

Tilray Brands achieved remarkable financial performance in Q4 2024, driven by strategic acquisitions and a focus on innovation. Despite challenges like price compression, the company remains optimistic about future growth opportunities. Tilray's commitment to quality products and innovation positions it well for continued success in the market.

Tilray Brands reports record Q1 revenue growth and global expansion

Tilray Brands delivered a robust performance in Q1 2025, showcasing strong revenue growth, margin improvement, and strategic expansion across its diversified product portfolio.
While facing challenges in a competitive landscape and evolving regulatory environment, Tilray's financial strength, international growth initiatives, and focus on innovation position it well for future success.
By capitalizing on opportunities in wellness products, expanding into new beverage categories, and leveraging strategic partnerships, Tilray is poised for continued growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution Business segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage Alcohol Business segment refers to the production, marketing, and sale of beverages. The Wellness Business segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

If you look at the long view, the recent past is a blip.

Down 30% in 6 Months: Is Tilray Still a Buy?

The cannabis company has some pretty big ambitions for the next few years.

Is Tilray a Buy?

TLRY stock represents one of the bigger Canadian cannabis operations -- and it has done well. But is that enough reason to buy Tilray now?

Tilray Received Some Good News, But Is It Enough?

Canopy Growth

Cronos Group

HEXO Corp

SNDL Inc.

An analyst initiated coverage on three of the stocks, but all of them fell as a result.

Why Canopy Growth, Cronos, Hexo, Sundial, and Tilray Stocks Are Plunging This Week

Barclays has issued a report that has cast doubt over an entire industry and has sent cannabis stocks plunging. Should you be worried?

Cannabis Stocks: How One Analyst Just Snuffed Out TLRY, CRON, CGC Stocks

Tilray, Inc. (NASDAQ:TLRY) shares are trading lower after Barclays initiated coverage on the stock with an Underweight rating and a $10 price target. Barclays analyst Gaurav Jain notes 'the US leaf touching businesses remain federally illegal and we see little likelihood of legalization under the Biden administration.

Why Tilray Shares Are Falling

Curaleaf Holdings, Inc.

Senator Schumer's "big boys" comment causes big losses for cannabis stocks.

Why Tilray, Cronos, and Curaleaf Stocks Dropped Today

Tilray is slowly moving into the U.S. but it may soon face dilution. TLRY stock could fall if shares are issued to reach a revenue goal.

Tilray Is Creeping Into the U.S., But Its Sales Goal May Lead to Dilution

Barclays analyst Guarav Jain on Thursday initiated coverage of three cannabis stocks but said their businesses are limited by the relatively small size of the legal market in Canada. Barclays launched overage of Tilray TLRY, -4.86% and Cronos CRON, -4.48% with an underweight rating and price targets of $10 and $5.50 respectively.

Barclays initiates coverage of Tilray, Cronos and Canopy Growth

AMC Entertainment

Advanced Micro Devices

Ford Motor Company

GameStop

NVIDIA

Palantir Technologies

PayPal

Tesla

United States Steel

Meme stocks are central to the retail investor revolution. However, only some of the top-mentioned picks on Reddit are actually worth buying.

The Top 10 Meme Stocks on Reddit: Should You Buy, Sell or Hold?

NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Tilray, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), invites all stockholders of record to attend the Annual Meeting of Stockholders (“Annual Meeting”) which will be held on November 22, 2021 at 11:00 a.m. EST. The record date for the Annual Meeting was September 24, 2021. In light of the ongoing public health crisis caused by the COVID-19 pandemic, the Annual Meeting will be held in a virtual format only, via live webcast over the internet.

Tilray to Webcast Annual Meeting of Stockholders on November 22, 2021

Village Farms International

Canadian Pot Stocks For Your List This Week The post Top Canadian Marijuana Stocks In November 2021 appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Top Canadian Marijuana Stocks In November 2021

New Republican-sponsored legislation to legalize cannabis is due to be presented today.

Why Tilray Shares Popped Monday

But despite the near constant bad news for the cannabis industry, aggressive investors should still buy TLRY stock under $11. The post Tilray Has More Bad News Harshing Their Mellow appeared first on InvestorPlace.

Tilray Has More Bad News Harshing Their Mellow

Producers have gotten into the habit of making incredibly aggressive forecasts.

1 Thing Canadian Cannabis Producers Should Stop Doing Right Now

Aurora Cannabis

Investors are wondering why are marijuana stocks up today and we've got the latest answer to that burning question for Friday! The post SNDL, TLRY, ACB, CGC: Why Are Marijuana Stocks Up Today?

SNDL, TLRY, ACB, CGC: Why Are Marijuana Stocks Up Today?

Investors have some reason to hope that Congress might pass a marijuana legalization bill sooner than previously expected.

Why Tilray, Aurora Cannabis, and Canopy Growth Stocks Just Popped

Canadian cannabis giant Tilray, Inc. (NASDAQ: TLRY) (TSX:TLRY) confirmed Thursday it will participate in two Jefferies investor conferences. Conferences Details  On Tuesday, November 16, 2021, the company will participate in the Jefferies Virtual West Coast Consumer Conference.

Tilray Joins Two Jefferies Investor Conferences – Healthcare And Consumer

NEW YORK, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Tilray, Inc. (“Tilray”) (NASDAQ: TLRY; TSX: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, announced that the Company will participate in two Jefferies investor conferences.

Tilray to Participate in Two Jefferies Investor Conferences

Marijuana legalization just got more probable -- and taxation more likely.

Why Aurora Cannabis, Canopy Growth, Tilray, and Sundial Growers Stocks Flamed Out on Wednesday

Weed stocks have been trading higher in the last couple of days with AdvisorShares Pure Cannabis ETF (ARCA: YOLO) currently up 11.94%, AdvisorShares Trust AdvisorShares Pure US Cannabis ETF (ARCA: MSOS) jumping 11.99%, and ETFMG U.S. Alternative Harvest ETF (ARCA: MJUS) also gaining 9.63%.  Why have cannabis stocks been trading higher for the week?

Marijuana Stock Wars: Tilray Vs. Aurora Cannabis

Renewed legalization efforts could spark a wave of acquisitions.

Why Cronos Group, Tilray, Sundial Growers, and Other Cannabis Stocks Soared Today

While the federal legalization of cannabis is a commonly cited potential catalyst for TLRY stock, investors shouldn't count on it. The post Why Tilray Investors Need to Assume the Worst-Case Scenario appeared first on InvestorPlace.

Why Tilray Investors Need to Assume the Worst-Case Scenario

JP Morgan rescinding news on cannabis stock restriction? GOP's legalization bill treats marijuana like alcohol?

$ACB Expands European Presence; $MSOS Sees Massive Volume Spike — Cannabis Daily November 8, 2021

Today, news of what could potentially be a big legislative win, as well as the recent infrastructure bill news, is boosting cannabis stocks. The post Cannabis Stocks: Why TLRY, CRON, ACB, SNDL Stocks Are Getting High Today appeared first on InvestorPlace.

News for Tilray Brands Stock (TLRY)